Financial Forecasts And GuidanceThe company raised its 2025-26 EBITDA forecasts, indicating confidence in future financial performance and further reinforcing the positive outlook.
Pharmacy Division PerformanceThe company's pharmacy division is a significant growth driver, with revenues reaching $2.9 billion, 6% above consensus, and driven by strong specialty and infusion performance.
Provider Segment GrowthProvider segment showed strong performance with revenue growth of 12% year over year, supported by strong growth in home health revenues and operational execution.